vTv Therapeutics Inc. is partnering with JDRF to fund a study on a drug therapy the biopharmaceutical company is developing to address diabetes.
JDRF, through the partnership, is providing $3 million for the phase 2 study of vTv Therapeutics’ oral drug. vTv Therapeutics (NASDAQ: VTVT) will also put up $3 million for the study, the High Point-based company said Wednesday.
The study will look at the effect of vTv Therapeutics’ TTP399 as an oral treatment for Type 1 diabetes, including whether…
vTv Therapeutics Inc. is partnering with JDRF to fund a study on a drug therapy the biopharmaceutical company is developing to address diabetes.
JDRF, through the partnership, is providing $3 million for the phase 2 study of vTv Therapeutics’ oral drug. vTv Therapeutics (NASDAQ: VTVT) will also put up $3 million for the study, the High Point-based company said Wednesday.
The study will look at the effect of vTv Therapeutics’ TTP399 as an oral treatment for Type 1 diabetes, including whether…